

Fabian aus dem Siepen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223015/publications.pdf>

Version: 2024-02-01

19
papers

800
citations

623574

14
h-index

794469

19
g-index

20
all docs

20
docs citations

20
times ranked

1446
citing authors

#	ARTICLE	IF	CITATIONS
1	T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 210-216.	0.5	217
2	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. <i>Clinical Research in Cardiology</i> , 2019, 108, 1324-1330.	1.5	93
3	Cardiac Amyloid Load. <i>Journal of the American College of Cardiology</i> , 2016, 68, 13-24.	1.2	76
4	Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 6319.	2.0	61
5	Noninvasive Risk Stratification of Patients With Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 502-510.	2.3	54
6	Left ventricular mechanics assessed by two-dimensional echocardiography and cardiac magnetic resonance imaging: comparison of high-resolution speckle tracking and feature tracking. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1370-1378.	0.5	52
7	Left ventricular long axis strain: a new prognosticator in non-ischemic dilated cardiomyopathy?. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 36.	1.6	51
8	Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. <i>Clinical Research in Cardiology</i> , 2015, 104, 640-647.	1.5	36
9	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. <i>Haematologica</i> , 2019, 104, 1451-1459.	1.7	29
10	Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 132-133.	1.4	26
11	Assessment of global longitudinal strain using standardized myocardial deformation imaging: a modality independent software approach. <i>Clinical Research in Cardiology</i> , 2015, 104, 591-602.	1.5	22
12	Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 132-141.	1.4	19
13	Limits of the possible: diagnostic image quality in coronary angiography with third-generation dual-source CT. <i>Clinical Research in Cardiology</i> , 2017, 106, 485-492.	1.5	18
14	Peak Vâ€™O ₂ is an independent predictor of survival in patients with cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 167-173.	1.4	16
15	Variability of cardiovascular magnetic resonance (CMR) T1 mapping parameters in healthy volunteers during long-term follow-up. <i>Open Heart</i> , 2018, 5, e000717.	0.9	9
16	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 91-99.	1.4	8
17	Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 661-673.	1.0	8
18	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. <i>Clinical Research in Cardiology</i> , 2021, 110, 579-590.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. <i>World Journal of Cardiology</i> , 2021, 13, 55-67.	0.5	2